Drugs / Coagulation Factor VIII
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT03598725 | Jan 2016 → Dec 2019 | hemophilia A | Beijing Children's Hospital | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05662319 Background | Feb 2023 → Mar 2027 expected | hemophilia | Sanofi | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Coagulation factor VIII | “Coagulation factor VIII (ATC code: B02BD02)” NCT05662319 ↗ |
| Modality | Protein / enzyme biologic | “Domastic plasma derived factor FVIII (with intermidiate vWF)” NCT03598725 ↗ |
| Route | Intravenous | “Route of administration: Intravenous (IV)” NCT05662319 ↗ |